Asthma variability in patients previously treated with β 2-agonists alone

William Calhoun, Laura B. Sutton, Amanda Emmett, Paul M. Dorinsky

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: According to national asthma guidelines, asthma severity can be classified as intermittent, mild, moderate, or severe on the basis of lung function, symptoms, nighttime awakenings, and exacerbations. Although it is widely believed that patients might not remain consistently in any given severity category over time, few studies have examined this directly. Objective: We sought to assess the variability in disease severity-control among patients with persistent asthma who have not yet received an asthma maintenance treatment. Methods: We performed an analysis of asthma severity-control over time in placebo-treated patients (n = 85) from 2 randomized, double-blind, 12-week clinical trials in patients with asthma previously receiving β 2-agonists alone. Asthma severity-control was assessed on the basis of morning percent predicted peak expiratory flow, albuterol use, and symptoms. Results: At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV1 of 64% of predicted value or albuterol use and symptoms on 4.7 and 6.0 days per week, respectively). The mean percentage of treatment weeks that patients met all criteria for intermittent, mild, moderate, and severe asthma were 9%, 14%, 71%, and 6%, respectively. On the basis of morning peak expiratory flow, patients were classified as having intermittent-mild, moderate, or severe disease on 52%, 41%, and 7% of days, respectively. With regard to days per week with albuterol use or asthma symptoms, patients spent 59% and 45% of weeks, respectively, in the intermittent and mild categories. Conclusion: Asthma control cannot be adequately assessed in many patients by using discrete point-in-time assessments of lung function, short-acting β-agonist use, or asthma symptoms. This might lead to underestimation of disease severity and contribute to inadequate therapy and, ultimately, asthma morbidity.

Original languageEnglish (US)
Pages (from-to)1088-1094
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume112
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Asthma
Albuterol
Lung
Therapeutics
Placebos
Clinical Trials
Guidelines
Morbidity

Keywords

  • Albuterol use
  • Asthma
  • Asthma severity
  • Asthma variability
  • Clinical trial
  • Lung function test
  • Symptoms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Asthma variability in patients previously treated with β 2-agonists alone. / Calhoun, William; Sutton, Laura B.; Emmett, Amanda; Dorinsky, Paul M.

In: Journal of Allergy and Clinical Immunology, Vol. 112, No. 6, 12.2003, p. 1088-1094.

Research output: Contribution to journalArticle

Calhoun, William ; Sutton, Laura B. ; Emmett, Amanda ; Dorinsky, Paul M. / Asthma variability in patients previously treated with β 2-agonists alone. In: Journal of Allergy and Clinical Immunology. 2003 ; Vol. 112, No. 6. pp. 1088-1094.
@article{47851d801df34655ae199fe98d47b572,
title = "Asthma variability in patients previously treated with β 2-agonists alone",
abstract = "Background: According to national asthma guidelines, asthma severity can be classified as intermittent, mild, moderate, or severe on the basis of lung function, symptoms, nighttime awakenings, and exacerbations. Although it is widely believed that patients might not remain consistently in any given severity category over time, few studies have examined this directly. Objective: We sought to assess the variability in disease severity-control among patients with persistent asthma who have not yet received an asthma maintenance treatment. Methods: We performed an analysis of asthma severity-control over time in placebo-treated patients (n = 85) from 2 randomized, double-blind, 12-week clinical trials in patients with asthma previously receiving β 2-agonists alone. Asthma severity-control was assessed on the basis of morning percent predicted peak expiratory flow, albuterol use, and symptoms. Results: At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV1 of 64{\%} of predicted value or albuterol use and symptoms on 4.7 and 6.0 days per week, respectively). The mean percentage of treatment weeks that patients met all criteria for intermittent, mild, moderate, and severe asthma were 9{\%}, 14{\%}, 71{\%}, and 6{\%}, respectively. On the basis of morning peak expiratory flow, patients were classified as having intermittent-mild, moderate, or severe disease on 52{\%}, 41{\%}, and 7{\%} of days, respectively. With regard to days per week with albuterol use or asthma symptoms, patients spent 59{\%} and 45{\%} of weeks, respectively, in the intermittent and mild categories. Conclusion: Asthma control cannot be adequately assessed in many patients by using discrete point-in-time assessments of lung function, short-acting β-agonist use, or asthma symptoms. This might lead to underestimation of disease severity and contribute to inadequate therapy and, ultimately, asthma morbidity.",
keywords = "Albuterol use, Asthma, Asthma severity, Asthma variability, Clinical trial, Lung function test, Symptoms",
author = "William Calhoun and Sutton, {Laura B.} and Amanda Emmett and Dorinsky, {Paul M.}",
year = "2003",
month = "12",
doi = "10.1016/j.jaci.2003.09.044",
language = "English (US)",
volume = "112",
pages = "1088--1094",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Asthma variability in patients previously treated with β 2-agonists alone

AU - Calhoun, William

AU - Sutton, Laura B.

AU - Emmett, Amanda

AU - Dorinsky, Paul M.

PY - 2003/12

Y1 - 2003/12

N2 - Background: According to national asthma guidelines, asthma severity can be classified as intermittent, mild, moderate, or severe on the basis of lung function, symptoms, nighttime awakenings, and exacerbations. Although it is widely believed that patients might not remain consistently in any given severity category over time, few studies have examined this directly. Objective: We sought to assess the variability in disease severity-control among patients with persistent asthma who have not yet received an asthma maintenance treatment. Methods: We performed an analysis of asthma severity-control over time in placebo-treated patients (n = 85) from 2 randomized, double-blind, 12-week clinical trials in patients with asthma previously receiving β 2-agonists alone. Asthma severity-control was assessed on the basis of morning percent predicted peak expiratory flow, albuterol use, and symptoms. Results: At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV1 of 64% of predicted value or albuterol use and symptoms on 4.7 and 6.0 days per week, respectively). The mean percentage of treatment weeks that patients met all criteria for intermittent, mild, moderate, and severe asthma were 9%, 14%, 71%, and 6%, respectively. On the basis of morning peak expiratory flow, patients were classified as having intermittent-mild, moderate, or severe disease on 52%, 41%, and 7% of days, respectively. With regard to days per week with albuterol use or asthma symptoms, patients spent 59% and 45% of weeks, respectively, in the intermittent and mild categories. Conclusion: Asthma control cannot be adequately assessed in many patients by using discrete point-in-time assessments of lung function, short-acting β-agonist use, or asthma symptoms. This might lead to underestimation of disease severity and contribute to inadequate therapy and, ultimately, asthma morbidity.

AB - Background: According to national asthma guidelines, asthma severity can be classified as intermittent, mild, moderate, or severe on the basis of lung function, symptoms, nighttime awakenings, and exacerbations. Although it is widely believed that patients might not remain consistently in any given severity category over time, few studies have examined this directly. Objective: We sought to assess the variability in disease severity-control among patients with persistent asthma who have not yet received an asthma maintenance treatment. Methods: We performed an analysis of asthma severity-control over time in placebo-treated patients (n = 85) from 2 randomized, double-blind, 12-week clinical trials in patients with asthma previously receiving β 2-agonists alone. Asthma severity-control was assessed on the basis of morning percent predicted peak expiratory flow, albuterol use, and symptoms. Results: At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV1 of 64% of predicted value or albuterol use and symptoms on 4.7 and 6.0 days per week, respectively). The mean percentage of treatment weeks that patients met all criteria for intermittent, mild, moderate, and severe asthma were 9%, 14%, 71%, and 6%, respectively. On the basis of morning peak expiratory flow, patients were classified as having intermittent-mild, moderate, or severe disease on 52%, 41%, and 7% of days, respectively. With regard to days per week with albuterol use or asthma symptoms, patients spent 59% and 45% of weeks, respectively, in the intermittent and mild categories. Conclusion: Asthma control cannot be adequately assessed in many patients by using discrete point-in-time assessments of lung function, short-acting β-agonist use, or asthma symptoms. This might lead to underestimation of disease severity and contribute to inadequate therapy and, ultimately, asthma morbidity.

KW - Albuterol use

KW - Asthma

KW - Asthma severity

KW - Asthma variability

KW - Clinical trial

KW - Lung function test

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=0345734196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345734196&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2003.09.044

DO - 10.1016/j.jaci.2003.09.044

M3 - Article

VL - 112

SP - 1088

EP - 1094

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -